Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
Our objective was to assess the economic impact of a new cytokine therapy that was being compared to standard therapy as supportive care in patients receiving autologous bone marrow transplantation for treatment of lymphoma.
We performed an economic study accompanying a multicenter, randomized, controlled clinical trial in academic medical centers.
One hundred and fifteen patients consented to participate in a parallel economic study of a randomized controlled trial of sequential IL-3 followed by GM-CSF vs GM-CSF alone after autologous bone marrow transplantation.
We measured costs and quality-adjusted survival over a 13-month follow-up period.
For the 13-month study period, the total cost estimates were $79892 (95% CI $69343 to $90544) for patients receiving GM-CSF alone and $89651 (95% CI $79769 to $102114) for patients receiving IL-3/GM-CSF.
The difference was not statistically significant.
During the 13-month study period, the total number of quality-adjusted life-months in the GM-CSF arm was 6.67 (95% CI 5.75 to 7.56) months, while the total number of quality-adjusted life-months in the IL-3 arm was 6.26 (95% CI 5.34 to 7.15) months.
The difference in quality-adjusted life-months between the two treatment arms was not statistically significant. (...)
Mots-clés Pascal : Lymphome non hodgkinien, Facteur stimulant colonie granulocyte macrophage, Interleukine 3, Hodgkin maladie, Homme, Cytokine, Autogreffe, Greffe, Moelle osseuse, Cellule hématopoïétique, Essai clinique, Immunothérapie, Analyse coût efficacité, Economie santé, Survie, Hémopathie maligne, Lymphoprolifératif syndrome, Lymphome
Mots-clés Pascal anglais : Non Hodgkin lymphoma, Granulocyte macrophage colony stimulating factor, Interleukin 3, Hodgkin disease, Human, Cytokine, Autograft, Graft, Bone marrow, Hematopoietic cell, Clinical trial, Immunotherapy, Cost efficiency analysis, Health economy, Survival, Malignant hemopathy, Lymphoproliferative syndrome, Lymphoma
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0195587
Code Inist : 002B27D02. Création : 11/09/1998.